Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

Northern Drilling Shares Tumble 23% Amid Market Turbulence

Loading stream...

(VIANEWS) - At 14:46 EST on Tuesday, shares of NORTHERN DRILLING (NODL.OL) plummeted by 23.82% to close at kr1.46 following an upward session, continuing a bearish trend in the stock market that also saw Oslo Bors Benchmark Index_GI decline by 0.53% and reach 1,302.13 as well. NORTHERN DRILLING last closed price was at kr1.91, 94.53% lower than its 52-week high price of 34.90

About NORTHERN DRILLING

Northern Drilling Ltd. provides offshore drilling services for the oil and gas industry. Specializing in ultra-deep water drilling environments, this Bermuda-based company was founded in 2017 as one of the premier providers. Established by Northern Drilling's Chief Driller Mark Dey in 2017, Northern Drilling is now one of the key players in offshore drilling services today.

Yearly Analysis

Technical Analysis

Equity Analysis

More news about NORTHERN DRILLING (NODL.OL).

Categories

stockMarket

Tags

Stock PriceNORTHERN DRILLINGPrice DownMarket Session NowStock Price DownStock Market NowNODL.OLMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com